Erratum: Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biologic diseasemodifying antirheumatic drugs

Benzer Materyaller

• Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs
  Yazar:: Charles-Schoeman, Christina, ve diğerleri
  Baskı/Yayın Bilgisi: (2016)
• Safety and Efficacy of Baricitinib in Patients Receiving Conventional Synthetic Disease-Modifying Antirheumatic Drugs or Corticosteroids
  Yazar:: van Vollenhoven, Ronald, ve diğerleri
  Baskı/Yayın Bilgisi: (2018)
• Efficacy and safety of tofacitinib for active rheumatoid arthritis with an inadequate response to methotrexate or disease-modifying antirheumatic drugs: a meta-analysis of randomized controlled trials
  Yazar:: Song, Gwan Gyu, ve diğerleri
  Baskı/Yayın Bilgisi: (2014)
• Indirect Treatment Comparison of the Efficacy and Safety of Sarilumab Monotherapy in Rheumatoid Arthritis Patients with Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs
  Yazar:: Choy, Ernest, ve diğerleri
  Baskı/Yayın Bilgisi: (2019)
• Tofacitinib 5 mg Twice Daily in Patients with Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs: A Comprehensive Review of Phase 3 Efficacy and Safety
  Yazar:: Bird, Paul, ve diğerleri
  Baskı/Yayın Bilgisi: (2019)